[ad_1]
Dynamic Technology Lab Private Ltd increased its stake in Evolus, Inc. (NASDAQ:EOLS – Free Report) by 80.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,037 shares of the company’s stock after acquiring an additional 15,151 shares during the quarter. Dynamic Technology Lab Private Ltd owned 0.05% of Evolus worth $410,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of the stock. Millennium Management LLC increased its stake in shares of Evolus by 1.7% in the 1st quarter. Millennium Management LLC now owns 1,392,028 shares of the company’s stock valued at $16,746,000 after acquiring an additional 23,605 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Evolus by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock valued at $400,000 after buying an additional 1,838 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Evolus in the 1st quarter valued at about $5,851,000. PDT Partners LLC acquired a new stake in shares of Evolus in the 1st quarter valued at about $730,000. Finally, Graham Capital Management L.P. grew its stake in shares of Evolus by 22.8% in the 1st quarter. Graham Capital Management L.P. now owns 57,694 shares of the company’s stock valued at $694,000 after buying an additional 10,731 shares during the period. Institutional investors own 90.69% of the company’s stock.
Insider Transactions at Evolus
In other Evolus news, Director Brady Stewart bought 30,000 shares of the business’s stock in a transaction dated Friday, August 15th. The shares were purchased at an average price of $6.82 per share, for a total transaction of $204,600.00. Following the purchase, the director directly owned 88,629 shares of the company’s stock, valued at approximately $604,449.78. This represents a 51.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $7.51, for a total value of $42,972.22. Following the completion of the transaction, the chief marketing officer owned 89,949 shares in the company, valued at $675,516.99. The trade was a 5.98% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.
Wall Street Analysts Forecast Growth
EOLS has been the subject of several research reports. BTIG Research restated a “buy” rating and issued a $18.00 target price on shares of Evolus in a research note on Monday. HC Wainwright reduced their target price on Evolus from $27.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Wall Street Zen downgraded Evolus from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Finally, Needham & Company LLC restated a “hold” rating and issued a $22.00 target price on shares of Evolus in a research note on Wednesday, August 6th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $21.25.
Read Our Latest Stock Report on EOLS
Evolus Stock Performance
NASDAQ EOLS opened at $7.51 on Friday. Evolus, Inc. has a 1 year low of $5.71 and a 1 year high of $17.82. The company has a debt-to-equity ratio of 22.00, a current ratio of 2.27 and a quick ratio of 1.86. The firm has a market cap of $485.75 million, a price-to-earnings ratio of -7.66 and a beta of 1.07. The company has a fifty day moving average price of $8.12 and a 200-day moving average price of $10.00.
Evolus Company Profile
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Read More
Receive News & Ratings for Evolus Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Evolus and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
ABMN Staff
Source link